Latvian Biomedical Research and Study Center

Riga, Latvia

Latvian Biomedical Research and Study Center

Riga, Latvia

Time filter

Source Type

Patent
Latvian Biomedical Research And Study Center | Date: 2017-03-01

An invention discloses Lyme disease vaccine by obtaining high immune response against surface protein BB069 from Borrelia burgdorferi, the causative agent of Lyme disease. Present invention includes a protein comprising amino acids identical at least 80% to modified Borrelia burgdorferi BB0689 protein (as set forth in SEQ ID 5), chemically coupled to bacteriophage Q virus-like particles. Said invention also relates with a method of production and purification of protein, comprising amino acids identical at least 80% to modified Borrelia burgdorferi BB0689 protein as set forth in SEQ ID 5.


Patent
Latvian Biomedical Research And Study Center | Date: 2017-03-01

A method for calculating the fetal ccfDNA fraction in maternal plasma comprising detecting the presence of fetus specific alleles (different from maternal alleles) of composition of common single nucleotide polymorphism (SNP) in a target polynucleotide in a subject, wherein the SNP comprises rs10873704, rs2316921, rs3991951, rs13142086, rs2598548, rs10155423, rs7683293, rs11132694, rs2287678, rs888726, rs7740992, rs11242795, rs7756422, rs6915731, rs9347210, rs9691429, rs4875906, rs10780162, rs2005486, rs3911483, rs2028902, rs2904516, rs2175938, rs1973118, rs6498782, rs3826238, rs11568105, rs2139261, rs4494584 and rs55969137, and wherein detecting the presence of the fetal specific alleles (different from maternal alleles) of SNP in the subject is indicative of the fetal ccfDNA fraction in maternal plasma.


Patent
Latvian Biomedical Research And Study Center | Date: 2017-03-01

The present invention relates to a novel recombinant cyclized human growth hormone (somatotropin) which can be used in medicine for treating conditions associated with growth hormone deficiency.


Baumanis V.,Latvian Biomedical Research and Study Center
Current aging science | Year: 2013

The shortening of telomeres with ageing is a well-documented observation; however, the reported number of nucleotides in telomeres varies between different laboratories and studies. Such variability is likely caused by ethnic differences between the populations studied. Until now, there were no studies that investigated the variability of telomere length in a senescent Latvian population of the most common mitochondrial haplogroups, defined as H (45%), U (25%), Y chromosomal N1c (40%) and R1a1 (40%). Telomere length was determined in 121 individuals in different age groups, including a control group containing individuals of 20-40 years old and groups of individuals between 60-70 years old, 71-80 years old, 81-90 years old, and above 90 years old. Telomere length was determined using the Southern blot telomeric restriction fragment assay (TRF). Decreased telomere length with ageing was confirmed, but a comparison of centenarians and individuals between 60-90 years of age did not demonstrate a significant difference in telomere length. However, significant variability in telomere length was observed in the control group, indicating probable rapid telomere shortening in some individuals that could lead up to development of health status decline appearing with ageing. Telomere length measured in mononuclear blood cells (MNC) was compared with the telomere length measured in whole peripheral white blood cells (WBC) using TRF. Telomere length in MNC was longer than in WBC for the control group with individuals 20 to 40 years old; in contrast, for the group of individuals aged 65 to 85 years old, measured telomere length was shorter in MNC when compared to WBC.


Zeltins A.,Latvian Biomedical Research and Study Center
Molecular Biotechnology | Year: 2013

Over the last three decades, virus-like particles (VLPs) have evolved to become a widely accepted technology, especially in the field of vaccinology. In fact, some VLP-based vaccines are currently used as commercial medical products, and other VLP-based products are at different stages of clinical study. Several remarkable advantages have been achieved in the development of VLPs as gene therapy tools and new nanomaterials. The analysis of published data reveals that at least 110 VLPs have been constructed from viruses belonging to 35 different families. This review therefore discusses the main principles in the cloning of viral structural genes, the relevant host systems and the purification procedures that have been developed. In addition, the methods that are used to characterize the structural integrity, stability, and components, including the encapsidated nucleic acids, of newly synthesized VLPs are analyzed. Moreover, some of the modifications that are required to construct VLP-based carriers of viral origin with defined properties are discussed, and examples are provided. © 2012 Springer Science+Business Media, LLC.


The present invention relates to a novel sortase A (SrtA) inhibitory compound N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetamide which can be used in medicine as anti-infective agent for treating gram-positive bacterial infection.


Patent
Latvian Biomedical Research And Study Center | Date: 2014-11-12

The present invention relates to a test for detecting Limb-Girdle Muscular Dystrophies (LGMD), especially LGMD Type-2 (LGMD-2). A test kit for detecting mutations associated with Limb-Girdle Muscular Dystrophies Type-2 (LGMD-2), characterized in that said test kit comprises a probes selected from the group consisting of SEQ ID Nos. 1 - 78.


Patent
Latvian Biomedical Research And Study Center | Date: 2015-05-20

A method for predicting in a subject a level of blood LDL-C linked with dyslipidemia comprising detecting the presence of composition of common single nucleotide polymorphism (SNP) in a target polynucleotide in a subject, wherein the SNP comprises rs1167998, rs10889353, rs541041, rs754524, rs949790, rs10474433, rs3846662, rs1883025, rs662799, rs2271293, rs2965101, rs4803750, rs157580, rs2075650 and rs405509, and wherein detecting presence of the SNP in the subject is indicative of a propensity or increased risk of developing a dyslipidemia.


The present invention relates to a novel sortase A (SrtA) inhibitory compound N-(2-(3-oxobenzo[d]isothiazol-2(3H)-yl)acetyl)adamantane-1-carbohydrazide which can be used in medicine as anti-infective agent for treating Gram-positive bacterial infection.


Patent
Latvian Biomedical Research And Study Center | Date: 2016-11-09

The present invention relates to a kit for detecting mutation or polymorphism in the human mitochondrial DNA (mtDNA) comprising probes of SEQ ID Nos. 1 to 96 for the detection and diagnosis of such a mitochondrial diseases as chronic progressive external ophthalmoplegia (CPEO), Kearns-Sayre syndrome (KSS), Leber hereditary optic neuropathy (LHON), mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy myopathy sensory ataxia (MEMSA), myoclonic epilepsy with ragged-red fibres (MERRF), mitochondrial recessive ataxia syndrome (MIRAS), neurogenic weakness with ataxia and retinitis pigmentosa (NARP), sensory ataxia neuropathy, dysarthria, ophthalmoplegia (SANDO), spinocerebellar ataxia with epilepsy (SCAE), Alpers-Huttenlocher syndrome, Pearson syndrome, Infantile myopathy and lactic acidosis or Leigh syndrome.

Loading Latvian Biomedical Research and Study Center collaborators
Loading Latvian Biomedical Research and Study Center collaborators